東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Designing Phase-change Contrast Agen...

Nyankima, Ange Gloria.

FindBook

Google Book

Amazon

博客來

Designing Phase-change Contrast Agents for Safe Diagnostic Ultrasound Imaging and Enhanced Therapeutic Outcomes.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Designing Phase-change Contrast Agents for Safe Diagnostic Ultrasound Imaging and Enhanced Therapeutic Outcomes./
作者:	Nyankima, Ange Gloria.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	176 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-05, Section: B.
Contained By:	Dissertations Abstracts International81-05B.
標題:	Biomedical engineering. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27680243
ISBN:	9781392359846

Designing Phase-change Contrast Agents for Safe Diagnostic Ultrasound Imaging and Enhanced Therapeutic Outcomes.
Nyankima, Ange Gloria.

Designing Phase-change Contrast Agents for Safe Diagnostic Ultrasound Imaging and Enhanced Therapeutic Outcomes. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 176 p.

Source: Dissertations Abstracts International, Volume: 81-05, Section: B.

Thesis (Ph.D.)--North Carolina State University, 2019.

This item must not be sold to any third party vendors.

Phase-change contrast agents (PCCAs) are positioned to improve the reach of diagnostic and therapeutic ultrasound. These contrast agents, also known as nanodroplets, are formulated with liquid perfluorocarbon cores, which result in smaller mean diameter and increased in vivo stability, as compared to their microbubble (MB) counterpart. When needed for imaging or therapy, PCCAs are vaporized, or activated, into a gas, whereas MBs are formulated as such. With a gas core, both agents will produce unique backscattered signal as a result of oscillating in an acoustic field. In contrast to MBs, PCCAs have the potential to expand the reach of ultrasound contrast agents (UCAs) beyond vascular barriers. This has vast advantages in diagnostic and therapeutic applications of ultrasound technology. The oscillating nature of UCAs can be utilized for more than just signal generation. Depending on the application, this phenomenon in vivo can induce biological effects that has the potential to injure surrounding tissue. For diagnostic purposes, imaging with UCAs should be optimized to minimize negative tissue response in the organ being examined. Alternatively, for therapeutic outcomes, an oscillating UCA is utilized to intentionally produce bioeffects to the surrounding tissue, including temporarily opening biological barriers that limit drug delivery. In order to achieve these goals of safe diagnostic imaging and enhanced therapeutic outcomes, it is necessary to optimize PCCA formulation with respect to the desired in vivo response. I hypothesize that by characterizing in vivo responses as a function of PCCA formulation, one can arrive at the ideal formulation for the desired ultrasound application. In my first objective, I will explore the use of PCCAs for diagnostic imaging. I will begin this objective by exploring potential bioeffects from MB-mediated contrast enhanced ultrasound (CEUS), which utilizes an imaging sequence involving high amplitude pulses which cause substantial microbubble disruption. With this understanding, I will proceed to investigate potential bioeffects from PCCA-mediated CEUS, particularly focusing on the vaporization phase of PCCA-mediated CEUS. In this study, bioeffects will be measured as a function of PCCA formulation. My second objective will be to identify an optimal PCCA formulation for enhanced thermal ablation. The pursuit will require investigating the lesion size and heating efficiency from exposing various PCCA formulations to high intensity focused ultrasound (HIFU) in a tissue-mimicking phantom. We will conclude with future directions of PCCA technology as a drug-delivering vehicle. It is my hope that this work will be utilized to further the advancement of PCCA technology, towards in vivo applications in diagnostic imaging and therapeutic applications with ultrasound.

ISBN: 9781392359846Subjects--Topical Terms:

535387
Biomedical engineering.
Subjects--Index Terms:

Ultrasound contrast agents

Designing Phase-change Contrast Agents for Safe Diagnostic Ultrasound Imaging and Enhanced Therapeutic Outcomes.
LDR:04022nmm a2200325 4500 001 2269085
005 20200908082328.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392359846
035 $a (MiAaPQ)AAI27680243
035 $a (MiAaPQ)NCState_Univ18402036917
035 $a AAI27680243
040 $a MiAaPQ $c MiAaPQ
100 1 $a Nyankima, Ange Gloria. $3 3546391
245 1 0 $a Designing Phase-change Contrast Agents for Safe Diagnostic Ultrasound Imaging and Enhanced Therapeutic Outcomes.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 176 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-05, Section: B.
500 $a Advisor: Chang, Xiao Sha;Chang, Emily;Jiang, Xiaoning;Gallippi, Caterina;Dayton, Paul.
502 $a Thesis (Ph.D.)--North Carolina State University, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Phase-change contrast agents (PCCAs) are positioned to improve the reach of diagnostic and therapeutic ultrasound. These contrast agents, also known as nanodroplets, are formulated with liquid perfluorocarbon cores, which result in smaller mean diameter and increased in vivo stability, as compared to their microbubble (MB) counterpart. When needed for imaging or therapy, PCCAs are vaporized, or activated, into a gas, whereas MBs are formulated as such. With a gas core, both agents will produce unique backscattered signal as a result of oscillating in an acoustic field. In contrast to MBs, PCCAs have the potential to expand the reach of ultrasound contrast agents (UCAs) beyond vascular barriers. This has vast advantages in diagnostic and therapeutic applications of ultrasound technology. The oscillating nature of UCAs can be utilized for more than just signal generation. Depending on the application, this phenomenon in vivo can induce biological effects that has the potential to injure surrounding tissue. For diagnostic purposes, imaging with UCAs should be optimized to minimize negative tissue response in the organ being examined. Alternatively, for therapeutic outcomes, an oscillating UCA is utilized to intentionally produce bioeffects to the surrounding tissue, including temporarily opening biological barriers that limit drug delivery. In order to achieve these goals of safe diagnostic imaging and enhanced therapeutic outcomes, it is necessary to optimize PCCA formulation with respect to the desired in vivo response. I hypothesize that by characterizing in vivo responses as a function of PCCA formulation, one can arrive at the ideal formulation for the desired ultrasound application. In my first objective, I will explore the use of PCCAs for diagnostic imaging. I will begin this objective by exploring potential bioeffects from MB-mediated contrast enhanced ultrasound (CEUS), which utilizes an imaging sequence involving high amplitude pulses which cause substantial microbubble disruption. With this understanding, I will proceed to investigate potential bioeffects from PCCA-mediated CEUS, particularly focusing on the vaporization phase of PCCA-mediated CEUS. In this study, bioeffects will be measured as a function of PCCA formulation. My second objective will be to identify an optimal PCCA formulation for enhanced thermal ablation. The pursuit will require investigating the lesion size and heating efficiency from exposing various PCCA formulations to high intensity focused ultrasound (HIFU) in a tissue-mimicking phantom. We will conclude with future directions of PCCA technology as a drug-delivering vehicle. It is my hope that this work will be utilized to further the advancement of PCCA technology, towards in vivo applications in diagnostic imaging and therapeutic applications with ultrasound.
590 $a School code: 0155.
650 4 $a Biomedical engineering. $3 535387
650 4 $a Medical imaging. $3 3172799
653 $a Ultrasound contrast agents
690 $a 0574
690 $a 0541
710 2 $a North Carolina State University. $3 1018772
773 0 $t Dissertations Abstracts International $g 81-05B.
790 $a 0155
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27680243